Overview

As genetic counseling is recommended for an increasing number of patients with cancer, institutions are looking for new strategies to meet this growing demand. By developing efficient genetic counseling and testing service delivery models, more patients may be able to access crucial testing and targeted cancer treatment.

Hear directly from a genetic counselor at a community health system and a genetic counselor at an academic medical center as they share examples of alternative service delivery models, challenges they faced during the implementation of these workflows, and their impact on expanding access to genetic testing for appropriate patients.

Key Topics Include:

• Strategies for accessible education in the pretest setting
• Frameworks to integrate patients, physicians, nurse navigators, and testing coordinators into the genetic counseling process
• Workflows to get genetic testing results quickly and streamline quality care

You can find this important roundtable discussion HERE.

Overview

As technology advances, surgeons need to develop tools to assess the value of new devices and initiatives in patient care. Surgeons will also need to understand the processes by which their institutions evaluate new technology for integration into the system.

Presented by:

• Freya R. Schnabel, MD
  Professor, Department of Surgery at NYU Grossman School of Medicine
  Director of Breast Surgery
  NYU Langone Health
  New York, NY

Overview

In this informative webinar, participants will learn more about:

• Early Detection & Intervention for Subclinical Lymphedema:
  Why It's Important for Our Patients
• Clinical Practice Guidelines & PREVENT Trial Analysis Updates:
  Evidence-Based Insights Supporting Early Detection of Lymphedema
• Operationalizing a Lymphedema Surveillance Program:
  Best Practices for Implementation & Patient Compliance

Overview

This session will educate the audience on how to incorporate genetic and genomic testing insights into clinical practice in order to guide personalized and preventative care and optimize surgical decision making for patients.

Presenters:

• David Weintritt, MD, FACS
  Breast Cancer Surgeon at Virginia Cancer Specialists
• Laura Brzeskiewicz, MS, CGC
  Manager, Medical Science Liaisons at Myriad Genetics

Overview

In Part 2 of our 3-Part series exploring the comprehensive genetics and genomics landscape in breast cancer, we'll dive into Risk Assessment and High-Risk Management. Come along as we explore strategies and tests to assess breast cancer risk and tools for implementing a high-risk breast program in your practice. Let's identify patients together who are at high risk for breast cancer so we can #BeatBreastCancer.

Overview

Join Eric Manahan, MD, MBA, FACS, a leading expert in general and breast surgery, as he shares insights on trending topics in genetic testing for breast cancer. In this webinar, Dr. Manahan covers the importance and underutilization of genetic testing in breast cancer, disparities in genetic testing, unlocking the potential of tumor genomics, exciting research opportunities, and much more. Don't miss out — register today to secure your spot and gain valuable insights on how to elevate your approach to patient care.

Overview

As an elite surgeon, you work so hard to do what’s best for your patients and achieve better outcomes, but you can’t see what you need to see in the operating room. Standard technologies lack the resolution to visualize microscopic features associated with early-stage disease in the margins.

Perimeter’s Optical Coherence Tomography (OCT), a category first technology, delivers ultra-high-resolution margin visualization, giving surgeons the ability to gain real-time clarity on margin status. The S-Series OCT offers 10x the resolution of X-ray and ultrasound at 2mm imaging depth, making it a suitable tool for imaging difficult-to-detect disease at the cellular level.

In this webinar, breast surgeons will discuss how OCT helps them control their outcomes and close with confidence.

Why Attend?

• Learn about how OCT provides surgeons with clarity and confidence in the OR
• Hear breast surgeons review cases with OCT technology
• Ask your questions during a live Q&A

Speakers:

• Amani Jambhekar, MD, MBA, FACS
  CHRISTUS St. Vincent
• Jennifer Titensor, MD,
  Utah Surgical Associates
• Catherine A. Ronaghan, MD, FACS
  St. Joseph’s/Candler

Overview

Discover the latest insights from a peer-reviewed study conducted by physicians at MD Anderson and UT Health Houston. This webinar will delve into the critical issue of reoperations in BCS, exploring the associated costs, complications, and profound impact on patients and healthcare systems. This webinar presents a unique opportunity to hear from Dr. Nina Tamirisa, contributing author in the MD Anderson and UT Health study, and Dr. Ted James, as they highlight:

• Trends in Reoperation Rates: Understand the current statistics and trends in reoperation rates following BCS.
• Implications for Patients and Healthcare Systems: Learn about the physical, emotional, and financial burdens reoperations place on patients and the broader healthcare system.
• Strategies to Reduce Reoperations: Gain insights into practices aimed at reducing reoperation rates.
• Live Q&A: Ask your questions to leading experts in the field.

Faculty:

• Nina Tamirisa, MD
  Breast Surgical Oncologist,
  MD Anderson Cancer Center
• Ted James, MD, MHCM, FACS
  Chief of Breast Surgical Oncology,
  Beth Israel Deaconess Medical Center

Overview

• Evaluate latest evidence regarding breast cancer gene mutations in the DNA damage repair (DDR) pathway (eg, BRCA, PALB2, ATM) and their implications on therapeutic and surgical decision-making
• Analyze recent breast cancer genetic testing guideline recommendations and the role of various members of the multidisciplinary team, including surgeons, advanced practice providers, genetic counselors, patient navigators, pharmacists, and nurses in optimizing genetic testing processes for eligible patients in the newly diagnosed breast cancer setting
• Individualize breast cancer treatment selection for DDR-mutated, early-stage and metastatic breast cancers based on the latest safety and efficacy trial data, guideline recommendations, and genetic testing results
• Employ multidisciplinary care coordination models as a means to effectively integrate genetic testing into clinical practice, including considerations for pre- and post-test counseling and informed consent, to optimize breast cancer management and overall outcomes

Overview

Overview

Join our expert faculty for this interactive symposium to explore the role of systemic neoadjuvant therapy and the importance of MDT collaboration in the treatment of HER2-positive early breast cancer. With your participation, questions and interactive polling, our expert panel will navigate the complexities of systemic neoadjuvant therapy and share best practice of how to seamlessly integrate guideline-based care in your practice. Through case study review, our expert faculty will dissect the complex and interlinking roles of each MDT member within clinical practice.

Program Objective

This meeting aims to bring together HCPs to:

• Explore the clinical benefits of systemic neoadjuvant therapy for eligible patients from multidisciplinary perspectives
• Discuss the importance of multidisciplinary team collaboration in optimizing patient outcomes in HER2-positive eBC
• Review case studies that underpin the importance of tailoring treatment to the individual patient

Speakers

• Dr Lee Schwartzberg
  Chief of Medical Oncology and Hematology, Renown Health / William N. Pennington Cancer Institute, NV
• Dr Brigid Killelea
  Co-Director of Oncoplastic Breast Surgery Program, Dana-Faber Institute, Boston, M
• Rachel M. Pink, MSN, AOCNP, FNP-C
  Oncology Nurse Practitioner, Mohtaseb Blood and Cancer Center, Henderson, NV

Overview

• Discuss trends in de-escalation of surgical management of the breast and axilla in patients with early-stage breast cancer
• Explore emerging data on de-escalation of axillary surgery
• Consider the implications of omitting axillary surgery on genomic testing and adjuvant chemotherapy decision-making

Overview

Dr. David Weintritt, MD, FACS and Kristin Lupton, PA-C from Virginia Cancer Specialists will discuss the importance of early detection and intervention for Breast Cancer-Related Lymphedema (BCRL) and provide their insights into operationalizing a Lymphedema Surveillance Program along with Body Composition monitoring for their patients. Hear their expert perspectives on the role of bioimpedance spectroscopy (BIS) technology as well as the latest clinical practice guidelines. Please submit your questions or comments to: zoomipdweb@impedimed.com.

Speakers

• David Weintritt, MD, FACS
  Virginia Cancer Specialists
  Founder of the National Breast Center Foundation
• Kristin Lupton, PA-C
  Virginia Cancer Specialists

Overview

Join us for an expert-led discussion on how the MyRisk® Test with RiskScore® enhances hereditary cancer risk assessment and supports the development of high-risk breast cancer clinics. This session will explore practical strategies for implementing a Breast Cancer Risk Assessment (BCRA) program, featuring real-world insights from breast surgeon, Barry Rosen, MD, FACS and TinaMarie Bauman, RN, APN, AGN-BC, ACGN, both from Advocate Good Shephard Hospital in Greater Chicago.

Learn how the Myriad Oncology™ suite of services and workflow solutions, along with the MyRisk Test with RiskScore, empower clinicians to identify high-risk, unaffected patients earlier and streamline care pathways for improved outcomes.

Overview

Join us as we explore how tumor-informed molecular residual disease (MRD) analysis has evolved as a valuable tool in the clinic for patients with breast cancer. In this session, we will review the various clinical challenges patients face and how MRD testing is being used to help inform the care pathway in the neoadjuvant, adjuvant and surveillance settings.

Speakers

• Angel Rodriguez, MD
  Medical Oncologist, Medical Director, Natera
• Erica Giblin, MD
  Breast Surgery, Surgical Oncology, Ascension St. Vincent
• Alice Ho, MD
  Radiation Oncology, Duke Cancer Institute

Overview

Dr Neil Love, president of Research To Practice (RTP), recently hosted a CME/MOC-accredited webinar, developed in collaboration with the American Society of Breast Surgeons, that focused on localized breast cancer and featured insights from medical oncologists and breast surgeons. As part of this initiative, RTP conducted a case-based survey of breast surgeons to assess clinical decision-making related to genetic testing and management strategies. The results of this survey served as the foundation for Dr Love’s conversation with Drs Kevin S Hughes and Mark Robson, who shared real-world cases, evidence-based recommendations and key research findings.

Topics Discussed

• Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes
• Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with BC — Dr Robson

Moderator

• Neil Love, MD
  Research To Practice
  Miami, Florida

Faculty

• Kevin S Hughes, MD
  Director of Cancer Genetics
  McKoy Rose Professor of Surgery
  Medical University of South Carolina
  Charleston, South Carolina
• Mark E Robson, MD
  Associate Attending Physician
  Clinical Genetics and Breast Medicine Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York

CME/MOC Information

Target Audience

This activity is intended for breast surgeons, medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, and other allied healthcare professionals involved in the treatment of breast cancer.

Accreditation Statement

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) and American Board of Surgery (ABS) — Continuous Certification (CC)

Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.25 (video) and 1.75 (audio) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program and 1.25 (video) and 1.75 (audio) MOC points in the American Board of Surgery’s (ABS) Continuous Certification program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please note, these programs have been specifically designed for the following specialties: medical oncology (ABIM) and complex general surgical oncology (ABS).

Overview

Join us for an in-depth discussion on Intraoperative Margin Assessment (IOMA) in Breast-Conserving Surgery and the transformative impact of the Histolog® Scanner. This session will cover key clinical data, oncological perspectives, and the pathology advantages of Histolog for margin assessment. Learn how this technology, supported by SHIELD study data, is reducing reoperations and improving patient outcomes. Hosted by Jonathon Tunstall, CEO of Pathology News.

The Histolog Scanner has demonstrated a reduction in reoperations from 30% to 10%, and a 67% reduction in very complex patients. Learn more about the value and the clinical data for the Histolog Scanner for interoperative margin assessment in breast cancer lumpectomies.

Speakers

• Prof. Michael Lux
  Head of the Cooperative Breast Center, Paderborn, and the Gynecological Cancer Center at St. Vincenz Hospital, Paderborn
• Dr. Mariana Felicia Sandor
  Senior Physician at St. Louise Women’s and Children’s Clinic, Paderborn, and St. Josefs Hospital, Salzkotten
• Prof. Moira Ragazzi
  Associate Professor at the University of Modena and Reggio Emilia

Overview

Join SAGA® Diagnostics for an expert-led discussion on how Pathlight™ molecular residual disease (MRD) testing is redefining early-stage breast cancer management. This session will highlight key findings from the TRACER study (Cancer Research, 2025) and explore how Pathlight™—SAGA’s novel MRD platform, leveraging structural variant detection for ultra-sensitive, highly specific monitoring in early-stage and ER+ breast cancer—is transforming precision oncology. Featuring real-world insights from Mitchell Elliott, MD, FRCPC, first author of the TRACER study and Medical Oncologist at Princess Margaret Cancer Centre, and Wendy Levin, MD, MS, Chief Clinical Officer at SAGA Diagnostics, learn how MRD testing is reshaping surveillance, treatment decisions, and the future of breast cancer care.

Overview

Silbiotech, Inc. will host a breakfast symposium on managing atypical hyperplasia patients using genomic test, BBDRisk Dx, for personalized clinical decision-making. The test is approved for coverage by Medicare, Medicare Advantage Plans, Medicaid of several States, UnitedHealthCare, BCBS of most States and several other commercial insurance agencies. The clinical study, test development, validation and publications will be presented. Data on several Case Reports will also be presented. Audience will have an opportunity to ask questions.

Topics to Be Discussed

• Breast Cancer Rates among Atypical Hyperplasia Patients
• Genomic Test for Personalized Risk Assessment
• Genomic Information for Informed Management

Speaker

• Indira Poola, PhD
  Lead Scientist for developing BBDRisk Dx Test
  Silbiotech, Inc.

Overview

Experiences, studies and decision-making around management of cavity and radiation considerations for contemporary BCS

Speakers

• Susan K. Boolbol, MD
  NuVance Health
• Shawna Willey, MD
  Inova Schar Cancer Institute
• Jennifer Gass, MD
  Brown, Women & Infants
• Sunny Mitchell, MD
  Montefiore Nyack Medical Center
• Patricia Clark, MD
  Parkview Health

Overview